ZURAZura Bio Ltdvs its industry peers
A metric-by-metric comparison of Zura Bio Ltd against Biological Products, (No Diagnostic Substances) — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZURAThis | $427M#9 | — | 4.2x#11 | — | — | -31.0%#12 | — | -67.6%#8 | — | — | 117.6%#2 | — |
| PRME | $566M#1 | — | 14.2x#14 | 122.2x#8 | 55.3%#3 | -2.7%#7 | -4498.1%#8 | -505.3%#13 | — | — | -38.9%#14 | — |
| RGNX | $530M#2 | — | 7.4x#12 | 3.1x#3 | 104.5%#2 | 14.6%#4 | -94.6%#2 | -270.2%#12 | — | — | -14.4%#10 | — |
| TECX | $527M#3 | — | 2.4x#8 | — | — | -27.9%#10 | — | -33125.9%#14 | -713.5%#4 | — | 72.5%#3 | — |
| DNA | $502M#4 | — | 1.2x#2 | 3.0x#1 | -25.1%#8 | 42.8%#2 | -185.3%#3 | -0.1%#2 | — | — | -31.0%#13 | — |
| EIKN | $484M#5 | — | 1.0x#1 | — | — | — | — | 0.0%#1 | — | — | — | — |
| KYTX | $441M#7 | — | 2.7x#9 | — | — | -26.5%#9 | — | -97.4%#10 | -107.1%#2 | — | 41.9%#5 | — |
| CABA | $434M#8 | — | 2.1x#6 | — | — | -44.9%#13 | — | -79.7%#9 | — | — | 16.9%#6 | — |
| ARTV | $420M#10 | — | 1.2x#3 | — | -100.0%#9 | -28.3%#11 | — | -24.1%#4 | — | — | 256.4%#1 | — |
| CCCC | $416M#11 | — | 1.7x#5 | 11.6x#6 | 1.0%#7 | 0.3%#5 | -320.5%#5 | -42.5%#5 | — | — | 2.1%#8 | — |
| EDIT | $415M#12 | — | 3.9x#10 | 10.2x#5 | 25.4%#4 | 32.5%#3 | -394.9%#6 | -152.0%#11 | — | — | -9.7%#9 | — |
| OCGN | $361M#13 | — | — | 81.8x#7 | 8.8%#6 | -25.9%#8 | -1425.7%#7 | — | — | — | -24.7%#12 | — |
| AGEN | $354M#14 | 2.6x#2 | — | 3.1x#2 | 10.4%#5 | 98.7%#1 | -17.7%#1 | — | — | — | 71.9%#4 | — |
| XFOR | $353M#15 | 2.5x#1 | 2.3x#7 | 10.1x#4 | 1273.2%#1 | -111.5%#15 | -247.4%#4 | -50.9%#7 | -582.0%#3 | — | 10.0%#7 | — |
| GRML | $454M#6 | — | 7.8x#13 | — | — | -71.6%#14 | — | -18.2%#3 | -14.6%#1 | — | -89.8%#15 | — |
| LXEO | $343M#16 | — | 1.5x#4 | 525.0x#9 | — | -1.7%#6 | -16706.0%#9 | -42.5%#6 | — | — | -23.4%#11 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-19.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice